Literature DB >> 7582865

The mutagenic potential of antiestrogens at the HPRT locus in V79 cells.

T T Rajah1, J T Pento.   

Abstract

Tamoxifen, a nonsteroidal antiestrogen is widely used in the treatment of breast cancer. Although clearly of clinical value, it produces adverse side effects associated with its estrogen agonist activity. This has led to the development of antiestrogens with less estrogen agonist activity. Analog II (1,1-dichloro-cis-2,3-diaryl cyclopropane) is a cyclopropyl compound which produces pure antiestrogenic activity in mice and inhibits the proliferation of breast cancer cells. Since the genotoxicity of Analog II has not been examined, the aim of the present study was to investigate the mutagenic potential of Analog II. The mutagenic effects of Analog II were studied at the hypoxanthine phosphoribosyl transferase (hprt) locus in Chinese hamster lung fibroblasts (V79 cell line) and compared to tamoxifen and estradiol. In this study Analog II was not mutagenic at the hprt locus in V79 cells and appeared to have less mutagenic potential than either estradiol or tamoxifen. However, an examination of the genotoxicity of metabolic products of these compounds will be necessary before definite conclusions can be drawn concerning their genotoxicity in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7582865

Source DB:  PubMed          Journal:  Res Commun Mol Pathol Pharmacol        ISSN: 1078-0297


  3 in total

1.  Estrogen action and prostate cancer.

Authors:  Jason L Nelles; Wen-Yang Hu; Gail S Prins
Journal:  Expert Rev Endocrinol Metab       Date:  2011-05

Review 2.  Epidemiology of Prostate Cancer.

Authors:  Prashanth Rawla
Journal:  World J Oncol       Date:  2019-04-20

3.  Somatic mutations in stilbene estrogen-induced Syrian hamster kidney tumors identified by DNA fingerprinting.

Authors:  Kamaleshwar P Singh; Deodutta Roy
Journal:  J Carcinog       Date:  2004-03-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.